Armodafinil for HCV+ Patients Starting IFN Treatment
ID Number 10-1662Principal Investigator(s)
Jeffrey J Weiss
Department(s) or Division(s)
Fatigue is one of the most common side effects of the treatment of hepatitis C infection with pegylated interferon. Armodafinil is an FDA approved medication for the treatment of narcolepsy and shift-work sleep disorder. This is a randomized placebo controlled study to determine whether patients randomly assigned to armodafinil have lower rates of missed doses, dose reductions or treatment discontinuation due to side effects in the first 12 weeks of treatment for hepatitis C infection than do placebo patients.
Recruiting Patients: Yes